Of Policies and Uncertainties
The US Preventive Services Task Force recently changed its guidance on aspirin as a preventative medication, a major policy shift....
America’s Medical Civil War
The Affordable Care Act has redefined federalism in America by creating new mechanisms for the state and nation to provide...
When Data Becomes Due Process
Prosecutors often use patient data to investigate physicians. But patient data is biased, lacking the robustness required of evidence. And...
COVID Vaccines for Kids
COVID-19 vaccines have been approved for children ages 5-11, a decision most had already anticipated. But lost in the predictability...
America United International, Protecting Individuals Against Judicial Misconduct
Dr. Zena Crenshaw-Logal has taken what she learned as an advocate for judicial reform to launch America United International.
The Media Has Failed Healthcare
The rise in healthcare journalism has led to a rise in biased healthcare articles – with many articles written through...
First Principles of Healthcare
First principles thinking attempts to break down complex concepts into its fundamental parts. When we apply this thinking to healthcare,...
Moderna, a Modern Medical Company
Moderna's decision to restrict the licensing rights of its vaccine came as a surprise to many. But for those who...
The DEA’s Long Game
The DEA recently issued a public health alert, warning of counterfeit pills. A seemingly odd alert given the DEA's restrictions...
Vaccine or Treatment
The public perceives the pandemic through binary thinking, as though playing a zero sum game. But healthcare is not binary....
Abortion’s Precedent
America's regulation of abortion sets a concerning precedent for all of healthcare. As we expand healthcare coverage, we must caution against...
What ‘Doing Research’ Really Means
A phrase we hear frequently of late, often among prominent personalities with little to no formal scientific training. We decode...
Videos
Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence
Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...
Read more